Search

A new Munich-based company that says its patented technologies can reduce household water consumption by 90 per cent on average is looking for more investment.

A British pharmaceutical distributor, Beckpharma Ltd., said it licensed two Cuban healthcare products to sell in Europe as part of a broader effort for trade links.

On the glut of patenting, BASF's rising research budget, football fever in the Commons, and other insights into R&D management

Some strange new ways of raising money are starting to emerge - but would-be borrowers and lenders are still making sense of them.

Better, brighter, faster – that's where photonic lasers are trying to take us. A lay guide to the technology.

With licensing and collaboration now the lifeblood of the drug industry, the annual BIO-Europe get-together was focused on partnering. Nuala Moran was there.

New regulations on the registration and testing of chemicals could have some problematic knock-on effects on European R&D – but they could also bring some lucrative work the way of contract research organisations.

A politician's gaffe highlights the gender gap in science. Political action, not talk, is what's needed to close it.

Scientists are moving around as never before. And, argues Jean Guinet from the OECD, that’s not necessarily a bad thing.

A new proposal from the European Investment Fund seeks to accelerate the success of European technology transfer projects. A noble idea, says Mary Lisbeth D'Amico in her fortnightly column, but no one has yet stepped up to foot the bill.

OrthoMimetics, the first technology spin-out from the Cambridge-MIT Institute, Cambridge, UK, has begun its search for initial funding.

A British start-up is betting it has a better way for television networks to watch their viewers watching them.

We interview Andrew Newland, head of a venture capital consultancy with a long-term strategy of working with scientists and inventors.

Venture capital’s refusal to continue support helped Cyan Technology into liquidation. Rebuilt by its management, Cyan is now wary of asking VCs for money.

It has been six years since a French biotech company made a stock market debut – and now two, BioAlliance and ExonHit, are doing so. Is the European market reawakening?

"Scientific work … must be done for itself, for the beauty of science." Marie Curie, chemist & physicist (1867 - 1934)